HIV associated nephropathy future or investigational therapies
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[2]
Overview
Therapies such as molecular targeting require more research.[1] Recently, there have been reports of successful kidney transplantation from HIV-positive donors to HIV-positive recipients.[2][3]
Future or Investigational Therapies
- Therapies such as molecular targeting for prevention or delaying the progression to end stage renal disease (ESRD) require more research. [1]
- Recently, there have been reports from USA and South Africa that have shown successful kidney transplantation from HIV-positive donors to HIV-positive recipients.[2][3]
- HIV superinfection and resistance to cART are among the most concerning risks in kidney transplantation in HIV-positive kidneys to HIV-positive recipients.[4]
- There is lack of data on the estimation of recurrent disease and long-term outcome is not clear.[1]
References
- ↑ 1.0 1.1 1.2 Menez S, Hanouneh M, McMahon BA, Fine DM, Atta MG (2018). “Pharmacotherapy and treatment options for HIV-associated nephropathy”. Expert Opin Pharmacother. 19 (1): 39–48. doi:10.1080/14656566.2017.1416099. PMC 6381591. PMID 29224373.
- ↑ 2.0 2.1 Muller E, Barday Z, Mendelson M, Kahn D (2015). “HIV-positive-to-HIV-positive kidney transplantation–results at 3 to 5 years”. N Engl J Med. 372 (7): 613–20. doi:10.1056/NEJMoa1408896. PMC 5090019. PMID 25671253.
- ↑ 3.0 3.1 Durand CM, Segev D, Sugarman J (2016). “Realizing HOPE: The Ethics of Organ Transplantation From HIV-Positive Donors”. Ann Intern Med. 165 (2): 138–42. doi:10.7326/M16-0560. PMC 4949150. PMID 27043422.
- ↑ Muller E, Barday Z (2018). “HIV-Positive Kidney Donor Selection for HIV-Positive Transplant Recipients”. J Am Soc Nephrol. 29 (4): 1090–1095. doi:10.1681/ASN.2017080853. PMC 5875954. PMID 29330339.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH